Impasse over Vertex CF drugs likely to continue despite NHS’s managed access offer

Despite including a key request from CF patient advocacy groups' wish list, a fresh proposal from NHS England is unlikely to break the three-year-long stalemate over access to Vertex's cystic fibrosis drugs.

NHS England's new offer would fund Orkambi ivacaftor/lumacaftor and Symkevi tezacaftor/ivacaftor for all eligible patients under a two-year managed access arrangement that would allow for

Read the full 571 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE